On Location

On Location

Updates from major medical meetings in the field of hematology/oncology

On location

Isatuximab Plus Carfilzomib: A New Standard for Relapsed/Refractory Myeloma?

The three-drug combination of the CD38-targeting antibody isatuximab plus carfilzomib and dexamethasone significantly improved progression-free survival (PFS) in patients with relapsed or refractory multiple...
On location

ANDROMEDA: Subcutaneous Daratumumab for Newly Diagnosed Light Chain Amyloidosis

Adding subcutaneous daratumumab to the combination of cyclophosphamide, bortezomib, and dexamethasone (CyBorD) resulted in deeper and more rapid hematologic responses and improved clinical outcomes,...
On location

Idecabtagene Vicleucel Demonstrates Deep, Durable Responses in Relapsed/Refractory Myeloma

The BCMA-targeted chimeric antigen receptor (CAR) T-cell therapy idecabtagene vicleucel (previously known as bb2121) induced responses in nearly three-quarters of patients with relapsed/refractory multiple...
On location

A New CAR T-Cell Target for T-Cell Acute Lymphocytic Leukemia?

The anti-CD7 chimeric antigen receptor (CAR) T-cell therapy TruUCAR GC027 demonstrated promising efficacy in treating adults with relapsed or refractory T-cell acute lymphoblastic leukemia...
On location

Adding Venetoclax to Azacitidine Improves Response and Survival Rates in Treatment-Naïve AML

A combination of the hypomethylating agent azacitidine and the small-molecule BCL2 inhibitor venetoclax was associated with a 34% reduction in the risk of death,...
On location

Ibrutinib Improves Response and Survival Rates in CNS Relapse of Mantle Cell Lymphoma

Compared with standard immunochemotherapy, treatment with ibrutinib was associated with higher response rates and survival rates in patients with mantle cell lymphoma (MCL) and...
On location

Pegcetacoplan Outperforms Eculizumab for Paroxysmal Nocturnal Hemoglobinuria

Results from the phase III PEGASUS trial suggest that the targeted C3 inhibitor pegcetacoplan improved hemoglobin levels better than eculizumab in patients with paroxysmal...
On location

Evaluating MBG453 Plus Decitabine or Azacitidine in High-Risk MDS and AML

The anti-TIM-3 checkpoint inhibitor MBG453, when added to decitabine or azacitidine, was associated with antileukemic activity and durable response rates in patients with higher-risk...
On location

Systemic Bevacizumab Improves Anemia, Reduces Bleeding in Hereditary Hemorrhagic Telangiectasia

Treatment with systemic bevacizumab reduced bleeding and significantly increased hemoglobin levels in patients with the rare bleeding disorder hereditary hemorrhagic telangiectasia (HHT), according to...
On location

DREAMM-6: Evaluating Belantamab Mafodotin and Bortezomib Plus Dexamethasone in Relapsed/Refractory Myeloma

Early data from the DREAMM-6 study suggest that the combination of belantamab mafodotin, bortezomib, and dexamethasone is active in patients with relapsed or refractory...
Advertisement

Current Issue

August 2020 Volume 6, Issue 10

This issue looks at the rapid expansion of telemedicine, explores access to leukemia treatment in Brazil, and more.

Block title